Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$209.17
-0.84-0.40%
At close: -
$209.25
0.080.04%
After Hours: 5:44 PM EDT
Comments
Loading...
AbbVie Analyst Ratings and Price Targets | NYSE:ABBV | Benzinga
AbbVie Inc has a consensus price target of $196.5 based on the ratings of 34 analysts. The high is $240 issued by Wells Fargo on March 5, 2025. The low is $133 issued by CFRA on February 9, 2023. The 3 most-recent analyst ratings were released by Wells Fargo, B of A Securities, and Citigroup on March 5, 2025, March 4, 2025, and February 3, 2025, respectively. With an average price target of $226 between Wells Fargo, B of A Securities, and Citigroup, there's an implied 8.05% upside for AbbVie Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wells Fargo
B of A Securities
Citigroup
Truist Securities
UBS
1calculated from analyst ratings
Analyst Ratings for AbbVie
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/05/2025 | Buy Now | 14.74% | Wells Fargo | Mohit Bansal73% | $210 → $240 | Maintains | Overweight | Get Alert |
| 03/04/2025 | Buy Now | 6.61% | B of A Securities | Tim Anderson53% | $200 → $223 | Maintains | Neutral | Get Alert |
| 02/03/2025 | Buy Now | 2.79% | Citigroup | Geoff Meacham63% | $205 → $215 | Maintains | Buy | Get Alert |
| 02/03/2025 | Buy Now | 3.74% | Truist Securities | Srikripa Devarakonda49% | $211 → $217 | Maintains | Buy | Get Alert |
| 02/03/2025 | Buy Now | -9.16% | UBS | Navin Jacob66% | $181 → $190 | Maintains | Neutral | Get Alert |
| 02/03/2025 | Buy Now | 0.4% | Wells Fargo | Mohit Bansal73% | $195 → $210 | Maintains | Overweight | Get Alert |
| 02/03/2025 | Buy Now | 14.26% | Morgan Stanley | Terence Flynn66% | $224 → $239 | Maintains | Overweight | Get Alert |
| 02/03/2025 | Buy Now | 5.18% | Raymond James | Gary Nachman58% | $218 → $220 | Reiterates | Outperform → Outperform | Get Alert |
| 02/03/2025 | Buy Now | 2.31% | Guggenheim | Vamil Divan76% | $212 → $214 | Maintains | Buy | Get Alert |
| 02/03/2025 | Buy Now | 2.79% | BMO Capital | Evan David Seigerman56% | $208 → $215 | Maintains | Outperform | Get Alert |
| 01/28/2025 | Buy Now | -1.99% | Citigroup | Geoff Meacham63% | $215 → $205 | Maintains | Buy | Get Alert |
| 01/08/2025 | Buy Now | 0.87% | Truist Securities | Srikripa Devarakonda49% | $215 → $211 | Maintains | Buy | Get Alert |
| 12/17/2024 | Buy Now | 5.18% | Piper Sandler | Christopher Raymond57% | $212 → $220 | Maintains | Overweight | Get Alert |
| 12/10/2024 | Buy Now | -8.69% | B of A Securities | Tim Anderson53% | → $191 | Reinstates | → Neutral | Get Alert |
| 11/22/2024 | Buy Now | -1.52% | Leerink Partners | David Risinger74% | → $206 | Upgrade | Market Perform → Outperform | Get Alert |
| 11/15/2024 | Buy Now | -1.99% | Wolfe Research | Alexandria Hammond43% | → $205 | Initiates | → Outperform | Get Alert |
| 11/13/2024 | Buy Now | -4.38% | JP Morgan | Chris Schott61% | $210 → $200 | Maintains | Overweight | Get Alert |
| 11/12/2024 | Buy Now | 2.79% | Citigroup | Geoff Meacham63% | $226 → $215 | Maintains | Buy | Get Alert |
| 11/12/2024 | Buy Now | -0.56% | BMO Capital | Evan David Seigerman56% | $228 → $208 | Maintains | Outperform | Get Alert |
| 11/12/2024 | Buy Now | 7.09% | Morgan Stanley | Terence Flynn66% | $231 → $224 | Maintains | Overweight | Get Alert |
| 11/06/2024 | Buy Now | 5.66% | Guggenheim | Vamil Divan76% | $212 → $221 | Maintains | Buy | Get Alert |
| 11/04/2024 | Buy Now | — | Argus Research | David Toung72% | — | Upgrade | Hold → Buy | Get Alert |
| 10/31/2024 | Buy Now | 9% | BMO Capital | Evan David Seigerman56% | $220 → $228 | Maintains | Outperform | Get Alert |
| 10/31/2024 | Buy Now | 8.05% | Citigroup | Geoff Meacham63% | $215 → $226 | Maintains | Buy | Get Alert |
| 10/31/2024 | Buy Now | -4.38% | UBS | Navin Jacob66% | $195 → $200 | Maintains | Neutral | Get Alert |
| 10/31/2024 | Buy Now | 10.44% | Morgan Stanley | Terence Flynn66% | $218 → $231 | Maintains | Overweight | Get Alert |
| 10/25/2024 | Buy Now | 2.79% | Citigroup | Andrew Baum72% | $170 → $215 | Maintains | Buy | Get Alert |
| 10/18/2024 | Buy Now | -6.77% | B of A Securities | Geoff Meacham63% | $185 → $195 | Maintains | Neutral | Get Alert |
| 10/17/2024 | Buy Now | 5.18% | BMO Capital | Evan David Seigerman56% | $214 → $220 | Maintains | Outperform | Get Alert |
| 10/17/2024 | Buy Now | -2.95% | Bernstein | Aaron Gal54% | → $203 | Initiates | → Market Perform | Get Alert |
| 10/10/2024 | Buy Now | 2.79% | Truist Securities | Srikripa Devarakonda49% | $210 → $215 | Maintains | Buy | Get Alert |
| 10/09/2024 | Buy Now | -6.77% | UBS | Navin Jacob66% | $185 → $195 | Maintains | Neutral | Get Alert |
| 10/07/2024 | Buy Now | 1.35% | Barclays | Carter Gould58% | $200 → $212 | Maintains | Overweight | Get Alert |
| 10/07/2024 | Buy Now | 7.57% | TD Cowen | Steve Scala70% | $195 → $225 | Maintains | Buy | Get Alert |
| 08/23/2024 | Buy Now | -0.08% | Piper Sandler | Christopher Raymond57% | $196 → $209 | Maintains | Overweight | Get Alert |
| 08/12/2024 | Buy Now | 4.22% | Morgan Stanley | Terence Flynn66% | $211 → $218 | Maintains | Overweight | Get Alert |
| 08/05/2024 | Buy Now | -4.38% | Cantor Fitzgerald | Louise Chen59% | $200 → $200 | Reiterates | Overweight → Overweight | Get Alert |
| 07/26/2024 | Buy Now | -11.56% | UBS | Navin Jacob66% | $172 → $185 | Maintains | Neutral | Get Alert |
| 07/26/2024 | Buy Now | -4.38% | Cantor Fitzgerald | Louise Chen59% | $200 → $200 | Reiterates | Overweight → Overweight | Get Alert |
| 07/26/2024 | Buy Now | 0.4% | Truist Securities | Robyn Karnauskas55% | $195 → $210 | Reiterates | Buy → Buy | Get Alert |
| 07/26/2024 | Buy Now | -1.99% | Wells Fargo | Mohit Bansal73% | $200 → $205 | Maintains | Overweight | Get Alert |
| 07/26/2024 | Buy Now | -4.38% | Barclays | Carter Gould58% | $187 → $200 | Maintains | Overweight | Get Alert |
| 07/25/2024 | Buy Now | 0.4% | JP Morgan | Chris Schott61% | $190 → $210 | Maintains | Overweight | Get Alert |
| 07/19/2024 | Buy Now | 2.31% | BMO Capital | Evan David Seigerman56% | $180 → $214 | Maintains | Outperform | Get Alert |
| 07/11/2024 | Buy Now | -6.3% | Morgan Stanley | Terence Flynn66% | $191 → $196 | Maintains | Overweight | Get Alert |
| 07/09/2024 | Buy Now | -4.38% | Cantor Fitzgerald | Louise Chen59% | $200 → $200 | Reiterates | Overweight → Overweight | Get Alert |
| 07/02/2024 | Buy Now | -9.16% | Piper Sandler | Christopher Raymond57% | $190 → $190 | Maintains | Overweight | Get Alert |
| 06/20/2024 | Buy Now | -4.38% | Cantor Fitzgerald | Louise Chen59% | $200 → $200 | Reiterates | Overweight → Overweight | Get Alert |
| 06/18/2024 | Buy Now | -9.16% | Piper Sandler | Christopher Raymond57% | $185 → $190 | Maintains | Overweight | Get Alert |
| 06/05/2024 | Buy Now | -11.56% | HSBC | Rajesh Kumar65% | → $185 | Upgrade | Hold → Buy | Get Alert |
| 05/17/2024 | Buy Now | -4.38% | Cantor Fitzgerald | Louise Chen59% | → $200 | Initiates | → Overweight | Get Alert |
| 04/29/2024 | Buy Now | -10.6% | Barclays | Carter Gould58% | $195 → $187 | Maintains | Overweight | Get Alert |
| 04/29/2024 | Buy Now | -13.95% | BMO Capital | Evan David Seigerman56% | $195 → $180 | Maintains | Outperform | Get Alert |
| 03/27/2024 | Buy Now | -6.77% | Barclays | Carter Gould58% | $185 → $195 | Maintains | Overweight | Get Alert |
| 03/22/2024 | Buy Now | -9.16% | Guggenheim | Vamil Divan76% | $188 → $190 | Maintains | Buy | Get Alert |
| 02/06/2024 | Buy Now | -9.64% | Raymond James | Gary Nachman58% | $181 → $189 | Maintains | Outperform | Get Alert |
| 02/06/2024 | Buy Now | -6.77% | Truist Securities | Robyn Karnauskas55% | $180 → $195 | Maintains | Buy | Get Alert |
| 02/05/2024 | Buy Now | -4.38% | Wells Fargo | Mohit Bansal73% | $180 → $200 | Maintains | Overweight | Get Alert |
| 02/05/2024 | Buy Now | -9.64% | Raymond James | Gary Nachman58% | $181 → $189 | Maintains | Outperform | Get Alert |
| 02/05/2024 | Buy Now | -6.77% | BMO Capital | Evan David Seigerman56% | $187 → $195 | Maintains | Outperform | Get Alert |
| 02/05/2024 | Buy Now | -11.56% | Barclays | Carter Gould58% | $175 → $185 | Maintains | Overweight | Get Alert |
| 01/29/2024 | Buy Now | — | William Blair | Tim Lugo34% | — | Upgrade | Market Perform → Outperform | Get Alert |
| 01/23/2024 | Buy Now | -16.34% | Barclays | Carter Gould58% | $170 → $175 | Maintains | Overweight | Get Alert |
| 01/02/2024 | Buy Now | -13.95% | Wells Fargo | Mohit Bansal73% | $195 → $180 | Maintains | Overweight | Get Alert |
| 12/18/2023 | Buy Now | -25.42% | HSBC | Rajesh Kumar65% | $167 → $156 | Downgrade | Buy → Hold | Get Alert |
| 12/11/2023 | Buy Now | -17.29% | Goldman Sachs | Chris Shibutani54% | → $173 | Upgrade | Neutral → Buy | Get Alert |
| 12/01/2023 | Buy Now | -13.47% | Raymond James | Gary Nachman58% | $177 → $181 | Maintains | Outperform | Get Alert |
| 11/09/2023 | Buy Now | -28.29% | Deutsche Bank | James Shin42% | → $150 | Initiates | → Hold | Get Alert |
| 10/30/2023 | Buy Now | -6.3% | Morgan Stanley | Terence Flynn66% | $193 → $196 | Maintains | Overweight | Get Alert |
| 10/30/2023 | Buy Now | -18.73% | Barclays | Carter Gould58% | $160 → $170 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 10/11/2023 | Buy Now | -7.73% | Morgan Stanley | Terence Flynn66% | $189 → $193 | Maintains | Overweight | Get Alert |
| 09/29/2023 | Buy Now | -15.38% | Raymond James | Gary Nachman58% | → $177 | Initiates | → Outperform | Get Alert |
| 07/28/2023 | Buy Now | -18.73% | Piper Sandler | Christopher Raymond57% | $163 → $170 | Maintains | Overweight | Get Alert |
| 07/25/2023 | Buy Now | — | William Blair | Tim Lugo34% | — | Initiates | → Market Perform | Get Alert |
| 07/14/2023 | Buy Now | -20.16% | HSBC | Rajesh Kumar65% | → $167 | Initiates | → Buy | Get Alert |
| 07/11/2023 | Buy Now | -12.99% | Morgan Stanley | Terence Flynn66% | $182 → $182 | Reiterates | Overweight → Overweight | Get Alert |
| 04/28/2023 | Buy Now | -18.25% | Guggenheim | Vamil Divan76% | $172 → $171 | Maintains | Buy | Get Alert |
| 04/28/2023 | Buy Now | -12.99% | Morgan Stanley | Terence Flynn66% | $181 → $182 | Maintains | Overweight | Get Alert |
| 04/28/2023 | Buy Now | -6.77% | Wells Fargo | Mohit Bansal73% | $200 → $195 | Maintains | Overweight | Get Alert |
| 04/13/2023 | Buy Now | -23.51% | Barclays | Carter Gould58% | $155 → $160 | Maintains | Equal-Weight | Get Alert |
| 04/10/2023 | Buy Now | -13.47% | Morgan Stanley | Terence Flynn66% | $178 → $181 | Maintains | Overweight | Get Alert |
| 04/05/2023 | Buy Now | — | Argus Research | Jasper Hellweg70% | — | Downgrade | Buy → Hold | Get Alert |
| 03/01/2023 | Buy Now | -17.77% | Guggenheim | Vamil Divan76% | → $172 | Initiates | → Buy | Get Alert |
| 02/22/2023 | Buy Now | — | Wolfe Research | Tim Anderson53% | — | Downgrade | Outperform → Peer Perform | Get Alert |
| 02/10/2023 | Buy Now | -27.33% | UBS | Navin Jacob66% | $150 → $152 | Maintains | Neutral | Get Alert |
| 02/10/2023 | Buy Now | -26.85% | SVB Leerink | David Risinger74% | $135 → $153 | Upgrade | Underperform → Market Perform | Get Alert |
| 02/10/2023 | Buy Now | -26.38% | Atlantic Equities | Steve Chesney55% | $157 → $154 | Maintains | Neutral | Get Alert |
| 02/10/2023 | Buy Now | -14.9% | Morgan Stanley | Terence Flynn66% | $182 → $178 | Maintains | Overweight | Get Alert |
| 02/10/2023 | Buy Now | -22.07% | Piper Sandler | Christopher Raymond57% | $157 → $163 | Maintains | Overweight | Get Alert |
| 02/09/2023 | Buy Now | -13.95% | Truist Securities | Robyn Karnauskas55% | → $180 | Reiterates | → Buy | Get Alert |
| 02/09/2023 | Buy Now | -21.12% | Evercore ISI Group | Gavin Clark-Gartner42% | $159 → $165 | Maintains | Outperform | Get Alert |
| 02/09/2023 | Buy Now | -36.42% | CFRA | — | $151 → $133 | Downgrade | Hold → Sell | Get Alert |
| 02/06/2023 | Buy Now | -20.16% | BMO Capital | Gary Nachman58% | $169 → $167 | Maintains | Outperform | Get Alert |
| 01/31/2023 | Buy Now | -28.29% | UBS | Navin Jacob66% | $147 → $150 | Maintains | Neutral | Get Alert |
| 01/17/2023 | Buy Now | -24.94% | Piper Sandler | Christopher Raymond57% | $155 → $157 | Maintains | Overweight | Get Alert |
| 01/05/2023 | Buy Now | -13.95% | Truist Securities | Robyn Karnauskas55% | $160 → $180 | Maintains | Buy | Get Alert |
| 12/20/2022 | Buy Now | -26.38% | Evercore ISI Group | Gavin Clark-Gartner42% | $156 → $154 | Maintains | Outperform | Get Alert |
| 12/14/2022 | Buy Now | -21.12% | B of A Securities | Geoff Meacham63% | $162 → $165 | Maintains | Neutral | Get Alert |
| 12/08/2022 | Buy Now | -19.2% | Exane BNP Paribas | Navaan Ty1% | → $169 | Initiates | → Neutral | Get Alert |
| 12/06/2022 | Buy Now | -12.99% | Morgan Stanley | Matthew Harrison60% | $178 → $182 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for AbbVie (ABBV) stock?
The latest price target for AbbVie (NYSE:ABBV) was reported by Wells Fargo on March 5, 2025. The analyst firm set a price target for $240.00 expecting ABBV to rise to within 12 months (a possible 14.74% upside). 54 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AbbVie (ABBV)?
The latest analyst rating for AbbVie (NYSE:ABBV) was provided by Wells Fargo, and AbbVie maintained their overweight rating.
When was the last upgrade for AbbVie (ABBV)?
The last upgrade for AbbVie Inc happened on November 22, 2024 when Leerink Partners raised their price target to $206. Leerink Partners previously had a market perform for AbbVie Inc.
When was the last downgrade for AbbVie (ABBV)?
The last downgrade for AbbVie Inc happened on December 18, 2023 when HSBC changed their price target from $167 to $156 for AbbVie Inc.
When is the next analyst rating going to be posted or updated for AbbVie (ABBV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AbbVie, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AbbVie was filed on March 5, 2025 so you should expect the next rating to be made available sometime around March 5, 2026.
Is the Analyst Rating AbbVie (ABBV) correct?
While ratings are subjective and will change, the latest AbbVie (ABBV) rating was a maintained with a price target of $210.00 to $240.00. The current price AbbVie (ABBV) is trading at is $209.17, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.